Portfolio

Current Investments


Cristal Therapeutics B.V.

Developing the next generation of nanomedicines.


InteRNA Technologies B.V.

Development of cancer therapies based on the unique functions miRNAs.


Inthera Bioscience AG

Drugs against ‘undruggable’ targets: Small Molecule Helix Mimetics.


ISA Pharmaceuticals B.V.

Fully synthetic therapeutic vaccines against cancer and persistent viral infections.


Macrophage Pharma Ltd.

A new therapeutic approach in immune-oncology, targeting the tumor microenvironment.


Modra Pharmaceuticals B.V.

Switching from intravenous-to-oral cancer treatment.


ORCA Therapeutics B.V.

Oncolytic adenovirus technologies.


Sapreme Technologies B.V.

Enabling endosomal escape of macromolecule therapeutics.


Somantix B.V.

Development of angiogenesis inhibitors for the treatment of solid cancers.


Listed Portfolio Companies


Merus N.V. – NASDAQ: MRUS

Bispecific antibodies which are targeting solid tumors and blood tumors.


Exited Portfolio Companies


Syntarga B.V.

Antibody Drug Conjugate Technologies.


News & Events